# Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients

> **NCT03250910** · PHASE4 · COMPLETED · sponsor: **National Taiwan University Hospital** · enrollment: 228 (actual)

## Conditions studied

- Hepatitis C Virus Infection, Response to Therapy of
- Human Immunodeficiency Virus

## Interventions

- **DRUG:** Sofosbuvir and Velpatasvir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT03250910
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-01
- **Primary completion:** 2017-07-15
- **Final completion:** 2017-10-31
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2017-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03250910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03250910, "Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03250910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*